Cerenis Therapeutics appoints Dr. Richard Pasternak as Chairman
Syntheses of Pantolactone and Pantothenic Acid Derivatives as Potential Lipid Regulating Agents
PR Cerenis July 2010 EN
Le Club Éco. Jean-Louis Dasseux, Cerenis Therapeutics : "Un marché potentiel de 35 milliards de dollars"
Cerenis Therapeutics se lance en Bourse: Jean-Louis Dasseux – 12/03 sur Orange Vidéos
Cerenis respecte son plan de marche» | Le Revenu
Cerenis Therapeutics se lance en Bourse: Jean-Louis Dasseux – 12/03
COMBINED GENERAL MEETING OF SHAREHOLDERS
Cerenis conserve son avance dans le HDL-mimétique | Le Revenu
HDL mimetic CER-001 targets atherosclerotic plaques in patients Kang He Zheng, Fleur M. van der Valk, Loek P. Smits, Mara Sandberg, Jean-Louis Dasseux, - ppt download
Finding The Right CRO For Rare Disease Trials
Cerenis Appoints Non-Executive Director, CMO - CBS Detroit
Effect of open-label infusion of an apoA-I-containing particle (CER-001) on RCT and artery wall thickness in patients with FHA[S
Jean-Louis Dasseux Net Worth (2023) | wallmine
Le Club Eco du 10-02-2011. Invité: Jean-Louis Dasseux, PDG de Cerenis Therapeutics - YouTube
Jean-Louis Dasseux, le cerveau de Cerenis - ladepeche.fr
Cerenis Therapeutics se lance en Bourse: Jean-Louis Dasseux – 12/03 sur Orange Vidéos
Dr. Jean-Louis Dasseux is the founder of Cerenis and one of the world's leading experts in lipid metabolism, lipid-protein int
Andrew MCKEE | Indiana University Bloomington, Indiana | IUB | Department of Chemistry | Research profile
CERENIS THERAPEUTICS - Interview de Jean-Louis DASSEUX, Fondateur et Directeur général - YouTube
Jean-Louis Dasseux, PhD, MBA, fondateur et Directeur Général de Cerenis - Biotech Agora
Long Hydrocarbon Chain Keto Diols and Diacids that Favorably Alter Lipid Disorders in Vivo | Journal of Medicinal Chemistry
Jean-Louis DASSEUX | Former CEO | PhD, MBA | Research profile
Cerenis Therapeutics se lance en Bourse: Jean-Louis Dasseux – 12/03 sur Orange Vidéos
PDF) Erratum to “α-Cycloalkyl-substituted ω-keto-dicarboxylic acids as lipid regulating agents” | Jean-Louis Dasseux - Academia.edu
Cerenis Therapeutics CEO and key executive team | Craft.co
